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Why?
Scientific:might	miss	out	on	an	important	discovery	(testing	too	few),	
or	find	a	clinically	irrelevant	effect	size	(testing	too	many)
Ethical:might	sacrifice	subjects	(testing	too	many)	or	unnecessarily
expose	too	few	when	study	success	chance	low	(testing	too	few)
Economical:might	waste	money	and	time	(testing	too	many)	or	have	to	
repeat	the	experiment	again	(testing	too	few)
Also,	generally	required	for	study	grant proposals
When?
• Should	be	determined	in	advance	of	the	study
• For	randomised	control	trials	(RCTs),	must	be	determined	and
specified	in	the	study	protocol	before recruitment	starts
What	not	to	do
Use	same	sample	size	as	another	(possibly	similar)	study
Might	have	just	gotten	lucky
Base	sample	size	on	what	is	available
Extend	study	period,	seek	more	money,	pool	study
Use	a	nice	whole	number	and	hope	no	one	notices
Unless	you	want	your	paper	rejected
Avoid	calculating	a	sample	size	because	you	couldn’t	estimate	the	parameters	needed
Do	a	pilot	study	or	use	approximate	formulae,	e.g.	SD	≈	(max	– min)	/	4
Avoid	calculating	a	sample	size	because	you	couldn’t	work	one	out
Speak	to	a	statistician
Example
• A	physician	wants	to	set	a	study	to	compare	a	new	
antihypertensive	drug relative	to	a	placebo
• Participants	are	randomized	into	two	treatment	groups:
• Group	N:	new	drug
• Group	P:	placebo
• The	primary	endpoint	is	taken	as	the	mean	reduction	in	systolic	
blood	pressure	(BPsys)	after	four	weeks
What	do	we	need?
Item Definition Specified value
Type	I	error	(⍺)
Power	(1	– β)
Minimal	clinically	relevant
difference	
Variation
Errors
No	evidence	of	a	
difference
Evidence	of	a	
difference
No	difference
True	Negative False	positive
Type	I	error (𝛼)
Difference	
False	negative
Type	II	error	(β)
True	PositiveTr
ut
h
Hypothesis	test
We	will	use	the	
conventional	
values	of	⍺=0.05	
and	β=0.20
What	do	we	need?
Item Definition Specified value
Type	I	error	(⍺) The	probability	of	falsely	rejecting	H0 (false	positive	rate) 0.05
Power	(1	– β) The	probability	of	correctly	rejecting	H0 (true	positive	rate) 0.80
Minimal	clinically	relevant
difference	
Variation
Minimal	clinically	relevant difference
• Minimal	difference	between	the	studied	groups	that	the	investigator	
wishes	to	detect	
• Referred	to	as	minimal	clinically	relevant	difference	(MCRD)	–
different	from	statistical	significance
• MCRD	should	be	biologically	plausible
• Sample	size	∝MCRD-2
• E.g.	if	n=100	required	to	detect	MCRD	=	1,	then	n=400	required	to	detect	
MCRD	=	0.5
• Note: some	software	/	formula	define	the	‘effect	size’	as	the	
standardized	effect	size	=	MCRD	/	σ
Where	to	get	MCRD	or	variation	values
• Biological	/	medical	expertise
• Review	the	literature
• Pilot	studies
• If	unsure,	get	a	the	range	of	values	and	explore	using	sensitivity	
analyses
Example:	continued
• From	previous	studies,	the	mean	BPsys of	hypertensive	patients	
is	145	mmHg	(SD	=	5	mmHg)
• Histograms	also	suggest	that	the	distribution	of	BP	is	normally	
distributed	in	the	population
• An	expert	says	the	new	drug	would	need	to	lower	BPsys by	5	
mmHg	for	it	to	be	clinically	significant,	otherwise	the	side	
effects	outweigh	the	benefit
• He	assumes	the	standard	deviation	of	BPsys will	be	the	same	in	
the	treatment	group
What	do	we	need?
Item Definition Specified value
Type	I	error	(⍺) The	probability	of	falsely	rejecting	H0 (false	positive	rate) 0.05
Power	(1	– β) The	probability	of	correctly	rejecting	H0 (true	positive	rate) 0.80
Minimal	clinically	relevant
difference	
The	smallest	(biologically	plausible)	
difference	in	the	outcome	that	is	
clinically	relevant
5	mmHg
Variation Variability	in	the	outcome	(SD	for	continuous outcomes) 5	mmHg
Sample	size	formula*
• 𝜇# − 𝜇% is	the	MCRD
• 𝑍' is	the	quantile	from	a	standard	normal	distribution
• 𝜎 is	the	common	standard	deviation
𝑛 ≈ 2 𝑍#,-. + 𝑍#,0 .𝜎.𝜇# − 𝜇% .
*based	on	a	two-sided	test	assuming	𝜎 is	known	
Sample	size	calculation
𝑛 ≈ 2 1.96 + 0.84 .5.5.𝑛 = 2 1.96 + 0.84 .5.5. = 15.7
Therefore	we	need	16	patients	per	treatment	group
NB: we	always	round	up,	never	down
Sensitivity	analyses
• Sample	size	sensitive	
to	changes	in	⍺,	β,	
MCRD,	σ
• Generally	a	good	idea	
to	consider	sensitivity	
of	calculation	to	
parameter	choices
• If	unsure,	generally	
choose	the	largest	
sample	size
Sample	size	calculation	software
• Standalone	tools:	G*Power	(http://www.gpower.hhu.de/)
• Many	statistics	software	packages	have	built-in	functions
• Lots	of	web-calculators	available
• Lots	of	formulae	published	in	(bio)statistics	papers
Practical	limitations
• What	if	the	study	duration	is	limited;	the	disease	rare;	financial	
resources	stretched;	etc.?
• Calculate	the	power	from	the	maximum	sample	size	possible	(reverse	
calculation)
• Possible	solutions:
• change	outcome	(e.g.	composite)
• use	as	an	argument	for	more	funding
• don’t	perform	the	study
• reduce	variation,	e.g.	change	scope	of	study
• pool	resources	with	other	centres
Estimation	problems
• Study	objective	may	be	to	estimate a	parameter	(e.g.	a	prevalence)	
rather	than	perform	a	hypothesis	test
• Sample	size,	n,	chosen	to	control	the	width	of	the	confidence	interval	(CI)
• E.g.	if	a	prevalence,	the	approximate	95%	CI is	given	by
𝑝< ± 1.96 𝑝<(1	–	𝑝<)𝑛  Margin	of	error	(MOE)
where	?̂? is	the	estimated	proportion
Example
• David	and	Boris	want	to	estimate	how	support	among	cardiothoracic	
surgeons	for	the	UK	to	leave	the	EU
• They	want	the	MOE	to	be	<3%
• SE	maximized	when	?̂? = 0.5,	so	need	#.@A. B  < 0.03
• So	need	to	(randomly)	poll	n =	1068	members
Drop-outs	/	missing	data
• Sample	size	calculation	is	for	the	number	of	subjects	providing	data
• Drop-outs	/	missing	data	are	generally	inevitable
• If	we	anticipate	losing	x%	of	subjects	to	drop-out	/	missing	data,	then	
inflate	the	calculated	sample	size,	n,	to	be:𝑛⋆ = 𝑛1 − 𝑥100
Sample	size	formula	and	software	available	
for	other…
• Effects:
• Comparing	two	proportions
• Hazard	ratios
• Odds	ratios
• …
• Study	designs:
• Cluster	RCTs
• Cross-over	studies
• Repeated	measures	(ANCOVA)
• …
• Hypotheses:
• Non-inferiority
• Superiority
• …
Observational	studies
Issues
• Study	design	features:
• Non-randomized	⇒ bias
• Missing	data
• Assignment	proportions	
unbalanced
• Far	fewer	‘closed-form’	formulae
How	to	approach (depending	on	
study	objective)
• Start	from	assuming	
randomization	as	a	reference
• Correction	factors	(e.g.	[1,2])
• Inflate	sample	size	for	PSM	to	
account	for	potential	unmatched	
subjects
• …
[1]	Hsieh	FY	et	al.	Stat	Med.	1998;	17:	1623–34.
[2]	Lipsitz SR	&	Parzen M.	The	Statistician.	1995;	1:	81-90.
Reporting
• Six	high-impact	journals	in	2005-06*:
• 5%	reported	no	calculation	details
• 43%	did	not	report	all	required	parameters
• Similar	reporting	inadequacies	in	papers	submitted	to	EJCTS/ICVTS
• Information	provided	should	(in	most	cases)	allow	the	statistical	
reviewer	to	reproduce the	calculation
• CONSORT	Statement
requirement
*	Charles	et	al.	BMJ 2009;338:b1732
Final	comments
• All	sample	size	formulae	depend	on	significance,	power,	MCRD,	
variability (+	possible	additional	assumptions	/	parameters,	e.g.	
number	of	events,	correlations,	…)	no	matter	how	complex
• Lots	of	published	formula	(search	Google	Sc )),	books,	software,	and	
of	course… statisticians	– need	to	find	the	one	right	for	your	study
• A	post	hoc power	calculation	is worthless
• Instead	report	effect	size	+	95%	CI
Thanks	for	listening
Any	questions?
Slides	available	(shortly)	from:	www.glhickey.com
I	need	more	
power,	Scotty
I	just	cannae do	it,	
Captain.	I	dinnae
have	the	poower!
Statistical	Primer	article	
to	be	published	soon!
